TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20614483

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Endorectal advancement flap (ERAF)
Number of subjects: 90
Study: 16538700

Group type: EXPERIMENTAL
Intervention: Hierarchical model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cluster-level methods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cluster-level summary measures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hierarchical modelling
Number of subjects: 0
Study: 15630387

Group type: EXPERIMENTAL
Intervention: Telescopic-assisted adenoidectomy using radiofrequency curette
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional adenoid-curette adenoidectomy
Number of subjects: 120
Study: 14703896

Group type: EXPERIMENTAL
Intervention: Captopril (Tensiomin)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sodium dimercaptosulphonate (DMPS)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no drug)
Number of subjects: 14
Study: 10885048

Group type: EXPERIMENTAL
Intervention: Puppet condition (P)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Unbiased questionnaire without puppet reference (Q)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Puppet method (P) after 1 month
Number of subjects: 395

Group type: COMPARATOR
Intervention: Unbiased questionnaire (Q) after 1 month
Number of subjects: 395
Study: 8895046

Group type: EXPERIMENTAL
Intervention: Nimodipine monotherapy
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Nimodipine combined with ketamine and lignocaine
Number of subjects: 115
Study: 1671993

Group type: EXPERIMENTAL
Intervention: Chloramphenicol with continuous application of an eyepad
Number of subjects: 30

Group type: COMPARATOR
Intervention: Chloramphenicol without the eyepad
Number of subjects: 30
Study: 6839761

Group type: EXPERIMENTAL
Intervention: TCu-22OC
Number of subjects: 1199

Group type: EXPERIMENTAL
Intervention: Multiload Cu250
Number of subjects: 1199

Group type: COMPARATOR
Intervention: Cu7
Number of subjects: 1199
Study: 30414998

Group type: EXPERIMENTAL
Intervention: Barbed suture (V‐Loc 90; Medtronic/Covidien)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Polyglactin 910 (coated Vicryl suture; Ethicon/Johnson & Johnson)
Number of subjects: 150
Study: 28342990

Group type: EXPERIMENTAL
Intervention: telephone-adapted Mindfulness-based Stress Reduction (tMBSR), an 8-week program of meditation and yoga
Number of subjects: 63

Group type: COMPARATOR
Intervention: telephone-based support group (tSupport)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: tMBSR
Number of subjects: 63

Group type: COMPARATOR
Intervention: tSupport
Number of subjects: 63
Study: 27178865

Group type: EXPERIMENTAL
Intervention: Facilitatory anodal tDCS (a‐tDCS)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham tDCS (s‐tDCS)
Number of subjects: 26
Study: 24430578

Group type: EXPERIMENTAL
Intervention: Polypropylene mesh fixed with polypropylene sutures (group A)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Self-fixating polypropylene mesh with resorbable polylactic acid microgrips (group B)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study: 22770932

Group type: EXPERIMENTAL
Intervention: Protein supplementation (2 * 15 g, twice daily)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups (Protein and Placebo)
Number of subjects: 62
Study: 19509020

Group type: EXPERIMENTAL
Intervention: Low-dose cortisol infusion (physiologic levels during hypoglycemia)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: High-dose cortisol infusion (twofold greater elevations of plasma cortisol)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hypoglycemic clamps (2.9 mmol/l)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Euglycemic clamps (5.1 mmol/l)
Number of subjects: 22
Study: 17244352

Group type: EXPERIMENTAL
Intervention: Tamoxifen for 2 years
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Tamoxifen for 5 years
Number of subjects: 677

Group type: EXPERIMENTAL
Intervention: Tamoxifen for 5 years (multivariate Cox model)
Number of subjects: 677

Group type: COMPARATOR
Intervention: Tamoxifen (general)
Number of subjects: 677
Study: 15998903

Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg daily)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg daily)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Combination of tamoxifen and anastrozole
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 124
Study: 11928797

Group type: EXPERIMENTAL
Intervention: Surgical and chemotherapeutic treatment
Number of subjects: 0
Study: 10093945

Group type: EXPERIMENTAL
Intervention: Ofloxacin (10 mg/kg/day in two divided doses for 5 days)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Cefixime (20 mg/kg/day in two divided doses for 7 days)
Number of subjects: 82
Study: 7486178

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (0.15, 0.45, 1.5 ppm)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous almitrine (16 micrograms.kg-1.min-1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Almitrine plus inhaled nitric oxide (1.5 ppm)
Number of subjects: 6
Study: 2030370

Group type: EXPERIMENTAL
Intervention: 100 mg/day tetrahydroaminoacridine (THA) and 10 g/day lecithin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7044195

Group type: EXPERIMENTAL
Intervention: Fluocortin butylester (FCB) 4 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 31600428

Group type: EXPERIMENTAL
Intervention: Potassium phosphite (PP) + Water Deficit (WD)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Hydrogen sulphide (HS) + Water Deficit (WD)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Zinc sulphate (ZS) + Water Deficit (WD)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Well-watered control (WW)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Water Deficit (WD)
Number of subjects: 5
Study: 31846014

Group type: EXPERIMENTAL
Intervention: Rocuronium (1.2 mg/kg)
Number of subjects: 1248

Group type: COMPARATOR
Intervention: Succinylcholine (1 mg/kg)
Number of subjects: 1248
Study: 28705122

Group type: EXPERIMENTAL
Intervention: Mobile application with active reminders of oral hygiene (3 times a day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Verbal oral hygiene instructions
Number of subjects: 44
Study: 26972780

Group type: EXPERIMENTAL
Intervention: TDF/FTC
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both groups (TDF/FTC and Placebo)
Number of subjects: 63
Study: 22672441

Group type: EXPERIMENTAL
Intervention: ePsychNurse.Net
Number of subjects: 137

Group type: COMPARATOR
Intervention: Training as usual (Control)
Number of subjects: 137
Study: 21396307

Group type: EXPERIMENTAL
Intervention: Glutamine-enriched TPN
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard TPN
Number of subjects: 50
Study: 18438249

Group type: EXPERIMENTAL
Intervention: Moderate plyometric training (2 days per week, 840 DJs)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Low plyometric training (1 day per week, 420 DJs)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High plyometric training (4 days per week, 1680 DJs)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (n = 10, 7 sessions of drop jump training, 1 day per week, 420 DJs)
Number of subjects: 42
Study: 16550733

Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg b.i.d. for 7 days plus norethisterone and ethinyl estradiol on Day 7
Number of subjects: 20

Group type: COMPARATOR
Intervention: OrthoNovum containing 1 mg norethisterone and 35 microg ethinyl estradiol
Number of subjects: 20
Study: 12687508

Group type: EXPERIMENTAL
Intervention: Self-management program (SMP) consisting of 3 group sessions and telephone follow-up.
Number of subjects: 211

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 211
Study: 10880410

Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg per day)
Number of subjects: 3090

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3090
Study: 9234037

Group type: EXPERIMENTAL
Intervention: Buspirone (15 mg/70 kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Buspirone (30 mg/70 kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.75 mg/70 kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Alprazolam (1.5 mg/70 kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Buspirone (15 mg/70 kg) + Ethanol (0‐0.6 g/kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Buspirone (30 mg/70 kg) + Ethanol (0‐0.6 g/kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Alprazolam (0.75 mg/70 kg) + Ethanol (0‐0.6 g/kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Alprazolam (1.5 mg/70 kg) + Ethanol (0‐0.6 g/kg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Ethanol (0‐0.6 g/kg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 1407749

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no coffee consumption)
Number of subjects: 0
Study: 3980799

Group type: EXPERIMENTAL
Intervention: Suberythemogenic doses of ultraviolet B (UVB) radiation with tar oil
Number of subjects: 49

Group type: COMPARATOR
Intervention: Maximally erythemogenic UVB radiation with emollients
Number of subjects: 49
Study: 30558284

Group type: EXPERIMENTAL
Intervention: Genetically predicted serum 25-hydroxyvitamin D concentrations
Number of subjects: 173005
Study: 26990315

Group type: EXPERIMENTAL
Intervention: Preoperative synbiotics
Number of subjects: 44

Group type: COMPARATOR
Intervention: No synbiotics (control group)
Number of subjects: 44
Study: 24445084

Group type: EXPERIMENTAL
Intervention: Treadmill-based supervised exercise training (SET) alone for 12 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Treadmill-based supervised exercise training (SET) combined with resistance training for 12 weeks
Number of subjects: 35
Study: 22150712

Group type: EXPERIMENTAL
Intervention: 10 motivational SMSs (MOTI)
Number of subjects: 2533

Group type: EXPERIMENTAL
Intervention: 3 motivational SMSs (MOTI)
Number of subjects: 2533

Group type: EXPERIMENTAL
Intervention: 3 informational SMSs (INFO)
Number of subjects: 2533

Group type: EXPERIMENTAL
Intervention: 10 informational SMSs (INFO)
Number of subjects: 2533

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2533
Study: 20401689

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 148

Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 148
Study: 18554874

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional antipsychotics
Number of subjects: 10
Study: 18037257

Group type: EXPERIMENTAL
Intervention: Foam body-support device
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard pressure sore prevention protocol (Control)
Number of subjects: 70
Study: 15586632

Group type: EXPERIMENTAL
Intervention: Attenuation corrected ECT values using the subtraction attenuation map
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clinical evaluation of attenuation corrected ECT values
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-corrected images
Number of subjects: 10
Study: 11754126

Group type: EXPERIMENTAL
Intervention: Intravenous clomipramine (IV CMI) 25 mg increasing to 250 mg by day 10, continuing to day 14
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intravenous clomipramine (IV CMI)
Number of subjects: 44
Study: 9249234

Group type: EXPERIMENTAL
Intervention: 50 mg mibefradil
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: 5 mg amlodipine
Number of subjects: 239

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 239
Study: 8514538

Group type: EXPERIMENTAL
Intervention: Topical ascorbic acid solution applied twice per day during radiotherapy
Number of subjects: 84

Group type: COMPARATOR
Intervention: Vehicle (placebo) applied twice per day during radiotherapy
Number of subjects: 84
Study: 2881130

Group type: EXPERIMENTAL
Intervention: Cyclosporin for 3 months followed by azathioprine and prednisone
Number of subjects: 72

Group type: COMPARATOR
Intervention: Azathioprine and prednisone from the day of transplantation (conventional group)
Number of subjects: 72
Study: 30401559

Group type: EXPERIMENTAL
Intervention: Combined obturator nerve block (ONB) and tibial nerve block (TNB) with continuous adductor canal block and local infiltration analgesia (LIA)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tibial nerve block (TNB) with continuous adductor canal block and local infiltration analgesia (LIA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Obturator nerve block (ONB) with continuous adductor canal block and local infiltration analgesia (LIA)
Number of subjects: 90
Study: 28704584

Group type: EXPERIMENTAL
Intervention: Combination of solifenacin 5 mg + mirabegron 25 mg
Number of subjects: 3527

Group type: EXPERIMENTAL
Intervention: Combination of solifenacin 5 mg + mirabegron 50 mg
Number of subjects: 3527

Group type: COMPARATOR
Intervention: Solifenacin 5 mg
Number of subjects: 3527

Group type: COMPARATOR
Intervention: Mirabegron 25 mg
Number of subjects: 3527

Group type: COMPARATOR
Intervention: Mirabegron 50 mg
Number of subjects: 3527

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3527
Study: 27688221

Group type: EXPERIMENTAL
Intervention: Community-based intervention (Phases II and III)
Number of subjects: 965

Group type: COMPARATOR
Intervention: Clinic-based intervention (Phase I)
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: Community-based intervention
Number of subjects: 965
Study: 25105475

Group type: EXPERIMENTAL
Intervention: High-frequency ultrasound (HFUS) at 1 MHz, 0.5 W/cm2, duty cycle of 20%, 1-3 minutes/cm2; one session per day, 5 days a week, in addition to standard wound care (SWC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard wound care (SWC) only
Number of subjects: 42
Study: 22257975

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Baseline (untreated)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison to healthy subjects
Number of subjects: 30
Study: 19129157

Group type: EXPERIMENTAL
Intervention: Intensive intervention group (personal telephone calls)
Number of subjects: 1181

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1181
Study: 17989547

Group type: EXPERIMENTAL
Intervention: Rehydration with approximately 1 l fluid for minor surgical procedures; 1-3 l fluid for moderate surgical procedures (laparoscopic surgery)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Administration of a carbohydrate-rich beverage preoperatively
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 15891265

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg) given twice daily for 14 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nizatidine (150 mg) given twice daily for 14 days
Number of subjects: 10
Study: 12489275

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy combined with fecal occult blood tests
Number of subjects: 0
Study: 9797854

Group type: EXPERIMENTAL
Intervention: Ethinyloestradiol (EE2)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oxandrolone (OX)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Normal girls (control group)
Number of subjects: 32
Study: 8130811

Group type: EXPERIMENTAL
Intervention: Experimental group (offering food based on need expressions and vegetable acceptance)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (maintained higher energy intake)
Number of subjects: 132
Study: 2492424

Group type: EXPERIMENTAL
Intervention: Hyperventilation (hypocapnia) during extinction phase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no hyperventilation)
Number of subjects: 0
Study: 31074821

Group type: EXPERIMENTAL
Intervention: Negative phase 3 RCTs without a phase 2 trial
Number of subjects: 64600

Group type: EXPERIMENTAL
Intervention: Negative phase 3 RCTs with a phase 2 trial available
Number of subjects: 64600

Group type: EXPERIMENTAL
Intervention: Negative phase 3 RCTs with a hazard ratio above 1.00
Number of subjects: 64600
Study: 27322159

Group type: EXPERIMENTAL
Intervention: Twice-weekly peer play psychotherapy (PPP)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Higher dosage of PPP
Number of subjects: 47

Group type: COMPARATOR
Intervention: Non-playgroup (NPG) children
Number of subjects: 47
Study: 25872588

Group type: EXPERIMENTAL
Intervention: Structured exercise training program (8-week outpatient program, combining endurance and resistance training, 3 sessions per week)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Structured exercise training program
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 96
Study: 23855816

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet
Number of subjects: 213

Group type: COMPARATOR
Intervention: Immediate-release oxycodone
Number of subjects: 213
Study: 21324954

Group type: EXPERIMENTAL
Intervention: World Health Organisation performance status (PS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mini-mental state examination (MMSE)
Number of subjects: 0
Study: 19035972

Group type: EXPERIMENTAL
Intervention: Budesonide 6 mg/day
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study: 17028986

Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD)
Number of subjects: 2576

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 2576

Group type: EXPERIMENTAL
Intervention: Family history of breast cancer
Number of subjects: 2576

Group type: EXPERIMENTAL
Intervention: Estradiol level
Number of subjects: 2576

Group type: EXPERIMENTAL
Intervention: Femoral neck BMD
Number of subjects: 2576

Group type: EXPERIMENTAL
Intervention: BMD and estradiol interaction
Number of subjects: 2576
Study: 15454247

Group type: EXPERIMENTAL
Intervention: Infused 5-fluorouracil (5FU) +/- mitomycin-C (MMC) for patients with oesophagogastric cancer who could not tolerate cis-platinum-containing regimens
Number of subjects: 1720

Group type: EXPERIMENTAL
Intervention: Chemotherapy for advanced disease
Number of subjects: 1720

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for colorectal cancer
Number of subjects: 1720
Study: 15648465

Group type: EXPERIMENTAL
Intervention: 5 hours time in bed
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 3 hours time in bed
Number of subjects: 26

Group type: COMPARATOR
Intervention: 8.5 hours time in bed (control group)
Number of subjects: 26
Study: 11296075

Group type: EXPERIMENTAL
Intervention: Healthy Steps for Young Children Program (HS)
Number of subjects: 4896
Study: 9030806

Group type: EXPERIMENTAL
Intervention: Normothermic CPB (warm group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hypothermic CPB (cold group)
Number of subjects: 40
Study: 8339807

Group type: EXPERIMENTAL
Intervention: Inhaled frusemide (40 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: 0.15 M NaCl control
Number of subjects: 19
Study: 3807448

Group type: EXPERIMENTAL
Intervention: Group practices
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional clinics
Number of subjects: 0
Study: 31778647

Group type: EXPERIMENTAL
Intervention: Anthocran®
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anthocran™ Phytosome™
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pure standards mimicking urinary fraction at 12 h
Number of subjects: 0
Study: 29358119

Group type: EXPERIMENTAL
Intervention: Low subjective socioeconomic status (SSS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 48
Study: 27343685

Group type: EXPERIMENTAL
Intervention: high-frequency transcranial random noise stimulation (hf-tRNS) with perceptual learning training (8 sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: sham stimulation with perceptual learning training (8 sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: hf-tRNS with no concurrent training
Number of subjects: 0
Study: 24636027

Group type: EXPERIMENTAL
Intervention: Povidone-iodine soaks 3 times daily
Number of subjects: 100

Group type: COMPARATOR
Intervention: Daily dressing changes
Number of subjects: 100
Study: 24294874

Group type: EXPERIMENTAL
Intervention: Increased alertness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation results
Number of subjects: 0
Study: 20048204

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg daily
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study: 18175337

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Sarizotan (2 mg/day)
Number of subjects: 484
Study: 16620167

Group type: EXPERIMENTAL
Intervention: Video intervention group (V) - traditional skilled nursing care at home and virtual visits using videoconferencing technology.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring intervention group (M) - traditional skilled nursing care at home, virtual visits using videoconferencing technology, and physiologic monitoring.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (C) - traditional skilled nursing care at home.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Video intervention group (V) and Monitoring intervention group (M) - evaluated by changes in the knowledge, behavior and status scales of the Omaha Assessment Tool.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face-to-face home visits (C)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Virtual visits (video group) (V)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring group visits for congestive heart failure (M)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring group visits for chronic obstructive pulmonary disease (M)
Number of subjects: 0